NHWK Stock Overview
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
NightHawk Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.11 |
| 52 Week High | US$3.42 |
| 52 Week Low | US$0.75 |
| Beta | 0.59 |
| 1 Month Change | 11.36% |
| 3 Month Change | -26.97% |
| 1 Year Change | -59.78% |
| 3 Year Change | -35.01% |
| 5 Year Change | -94.46% |
| Change since IPO | -99.83% |
Recent News & Updates
Recent updates
Here's Why We're Watching Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Dec 28
Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Sep 02Heat Biologics names Anthony Manning as chief scientific advisor
May 10Heat Biologics EPS misses by $0.01, misses on revenue
May 05We're Hopeful That Heat Biologics (NASDAQ:HTBX) Will Use Its Cash Wisely
Apr 30Reflecting on Heat Biologics' (NASDAQ:HTBX) Share Price Returns Over The Last Five Years
Mar 07Here's Why We're Not Too Worried About Heat Biologics' (NASDAQ:HTBX) Cash Burn Situation
Jan 13
Heat Biologics signs a licensing agreement; Appoints new CFO
Jan 06Heat Biologics soars 14% on completion of ZVX-60 vaccine cell line for COVID-19
Dec 16Introducing Heat Biologics (NASDAQ:HTBX), The Stock That Zoomed 124% In The Last Year
Nov 20Heat Biologics Provides Update, And Other News: The Good, Bad And Ugly Of Biopharma
Nov 02Shareholder Returns
| NHWK | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.9% | -0.8% | 0.9% |
| 1Y | -59.8% | 3.9% | -10.9% |
Return vs Industry: NHWK underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: NHWK underperformed the US Market which returned -10.9% over the past year.
Price Volatility
| NHWK volatility | |
|---|---|
| NHWK Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NHWK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: NHWK's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 49 | Jeff Wolf | https://www.nighthawkbio.com |
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company’s therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.
NightHawk Biosciences, Inc. Fundamentals Summary
| NHWK fundamental statistics | |
|---|---|
| Market Cap | US$28.48m |
| Earnings (TTM) | -US$44.85m |
| Revenue (TTM) | US$6.92m |
4.1x
P/S Ratio-0.6x
P/E RatioIs NHWK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NHWK income statement (TTM) | |
|---|---|
| Revenue | US$6.92m |
| Cost of Revenue | US$28.70m |
| Gross Profit | -US$21.78m |
| Other Expenses | US$23.06m |
| Earnings | -US$44.85m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.75 |
| Gross Margin | -314.98% |
| Net Profit Margin | -648.41% |
| Debt/Equity Ratio | 0% |
How did NHWK perform over the long term?
See historical performance and comparison